Synthesis and biological evaluation of N(9)-substituted harmine derivatives as potential anticancer agents
Copyright © 2016. Published by Elsevier Ltd..
A series of N(9)-substituted harmine derivatives were synthesized and evaluated for their anticancer activity on a panel of cancer cell lines, their apoptosis induction and their cell cycle effects. The results showed that N(9)-substituted harmine derivatives had anticancer effects. In particular, N(9)-haloalkyl derivatives 9a-9c and N(9)-acyl harmine derivatives 11c and 11d, with IC50 values less than 1μM, were more potent than doxorubicin against A-549 and/or MCF-7 cell lines. Moreover, structure-activity relationships (SARs) indicated that introducing a haloalkyl or benzenesulfonyl group in the N(9)-position of harmine could significantly increase the anticancer activity. The most active compound (11d) caused cell cycle arrest in the G2/M phase, and induced cell apoptosis in a dose-dependent manner.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Bioorganic & medicinal chemistry letters - 26(2016), 16 vom: 15. Aug., Seite 4015-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Du, Hongtao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4FHH5G48T7 |
|---|
| Anmerkungen: |
Date Completed 26.07.2017 Date Revised 22.11.2017 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bmcl.2016.06.087 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM262247194 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM262247194 | ||
| 003 | DE-627 | ||
| 005 | 20231224201337.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bmcl.2016.06.087 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0874.xml |
| 035 | |a (DE-627)NLM262247194 | ||
| 035 | |a (NLM)27397495 | ||
| 035 | |a (PII)S0960-894X(16)30698-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Du, Hongtao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synthesis and biological evaluation of N(9)-substituted harmine derivatives as potential anticancer agents |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.07.2017 | ||
| 500 | |a Date Revised 22.11.2017 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2016. Published by Elsevier Ltd. | ||
| 520 | |a A series of N(9)-substituted harmine derivatives were synthesized and evaluated for their anticancer activity on a panel of cancer cell lines, their apoptosis induction and their cell cycle effects. The results showed that N(9)-substituted harmine derivatives had anticancer effects. In particular, N(9)-haloalkyl derivatives 9a-9c and N(9)-acyl harmine derivatives 11c and 11d, with IC50 values less than 1μM, were more potent than doxorubicin against A-549 and/or MCF-7 cell lines. Moreover, structure-activity relationships (SARs) indicated that introducing a haloalkyl or benzenesulfonyl group in the N(9)-position of harmine could significantly increase the anticancer activity. The most active compound (11d) caused cell cycle arrest in the G2/M phase, and induced cell apoptosis in a dose-dependent manner | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Anticancer activities | |
| 650 | 4 | |a Apoptosis | |
| 650 | 4 | |a Cell cycle arrest | |
| 650 | 4 | |a Harmine derivatives | |
| 650 | 4 | |a Structure–activity relationships (SARs) | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Harmine |2 NLM | |
| 650 | 7 | |a 4FHH5G48T7 |2 NLM | |
| 700 | 1 | |a Tian, Shan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Juncheng |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Hongling |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Na |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Junru |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioorganic & medicinal chemistry letters |d 1992 |g 26(2016), 16 vom: 15. Aug., Seite 4015-9 |w (DE-627)NLM09063828X |x 1464-3405 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2016 |g number:16 |g day:15 |g month:08 |g pages:4015-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bmcl.2016.06.087 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2016 |e 16 |b 15 |c 08 |h 4015-9 | ||